Log in
Enquire now
‌

US Patent 11667911 Use of exonucleases to improve CRISPR/CAS-mediated genome editing

OverviewStructured DataIssuesContributors

Contents

Is a
Patent
Patent
0

Patent attributes

Patent Applicant
Editas Medicine
Editas Medicine
0
Current Assignee
Editas Medicine
Editas Medicine
0
Patent Jurisdiction
United States Patent and Trademark Office
United States Patent and Trademark Office
0
Patent Number
116679110
Date of Patent
June 6, 2023
0
Patent Application Number
157619680
Date Filed
September 23, 2016
0
Patent Citations
‌
US Patent 8889418 Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
0
‌
US Patent 8895308 Engineering and optimization of improved systems, methods and enzyme compositions for sequence manipulation
0
‌
US Patent 8945839 CRISPR-Cas systems and methods for altering expression of gene products
0
‌
US Patent 8993233 Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
0
‌
US Patent 8999641 Engineering and optimization of systems, methods and compositions for sequence manipulation with functional domains
0
‌
US Patent 9023649 RNA-guided human genome engineering
0
‌
US Patent 9228208 Methods and compositions for the targeted modification of a genome
0
‌
US Patent 9234213 Compositions and methods directed to CRISPR/Cas genomic engineering systems
0
...
Patent Primary Examiner
‌
Nancy J Leith
0

The present disclosure is directed to methods of producing a modified nucleic acid comprising a precise deletion in a target nucleic acid in a cell comprising generating, within the cell, a first single strand break on a first strand of the target nucleic acid and a second single strand break on a second strand of the target nucleic acid, thereby forming a double strand break in the target nucleic acid having a first 3′ overhang and a second 3′ overhang; processing the first 3′ overhang and the second 3′ overhang with an exonuclease molecule, thereby deleting the segment of the target nucleic acid that was located between the first single strand break and the second single strand break, and forming a processed double strand break; and allowing the processed double strand break to be repaired by at least one DNA repair pathway, thereby producing the modified nucleic acid comprising the precise deletion in the target nucleic acid in the cell. Gene editing systems, vectors, polynucleotides, and methods of treatment are also disclosed herein.

Timeline

No Timeline data yet.

Further Resources

Title
Author
Link
Type
Date
No Further Resources data yet.

References

Find more entities like US Patent 11667911 Use of exonucleases to improve CRISPR/CAS-mediated genome editing

Use the Golden Query Tool to find similar entities by any field in the Knowledge Graph, including industry, location, and more.
Open Query Tool
Access by API
Golden Query Tool
Golden logo

Company

  • Home
  • Press & Media
  • Blog
  • Careers
  • WE'RE HIRING

Products

  • Knowledge Graph
  • Query Tool
  • Data Requests
  • Knowledge Storage
  • API
  • Pricing
  • Enterprise
  • ChatGPT Plugin

Legal

  • Terms of Service
  • Enterprise Terms of Service
  • Privacy Policy

Help

  • Help center
  • API Documentation
  • Contact Us
By using this site, you agree to our Terms of Service.